Eli Lilly Shares Slip 4.1% in Five Days Despite 375% Five-Year Rise
Eli Lilly shares have climbed 375% over the past five years on GLP-1 drug momentum but have fallen 4.1% in the last five days and 9% year-to-date. Analysts forecast earnings growth of 41.1% in 2026 and 22.8% in 2027 while the stock trades at a 29.4 forward P/E.
1. Stock Performance
Eli Lilly shares have surged 375% over the past five years driven by its GLP-1 drug portfolio but experienced a 4.1% pullback over the last five days and are down 9% year-to-date, reflecting investor rotation and profit-taking.
2. Earnings and Valuation Outlook
Analysts expect Eli Lilly to deliver 41.1% earnings growth in 2026 and 22.8% in 2027. The shares trade at a forward P/E of 29.4, raising questions about valuation amid high growth forecasts and market volatility.
Related News
SLAB
Silicon Labs SoC Powers 500,000 Wi-SUN Module Shipment for India Grid
SLAB•
TOL
Toll Brothers Beats Q2 Revenue Guidance by $110M, Raises Delivery and Buyback Plans
TOL•
SVM
Silvercorp Secures 30-Year License Extension, Pays $60M for Tulkubash/Kyzyltash JV
SVM•
EXOD
Exodus Movement April XO Swap Volume Up 44% to $98M, Global Pay Launch
EXOD•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
Sources
F